148 related articles for article (PubMed ID: 37611260)
1. The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.
Chang X; Lv C; Wang B; Wang J; Song Z; An L; Chen S; Chen Y; Shang Q; Yu Z; Tan L; Li Q; Liu H; Jiang L; Xiao G; Chen L; Lu W; Hu X; Dong Z; Chen Y; Sun Y; Wang X; Li Z; Chen D; You H; Jia J; Yang Y
Hepatology; 2024 Feb; 79(2):425-437. PubMed ID: 37611260
[TBL] [Abstract][Full Text] [Related]
2. [Qualitative pathological assessment of liver fibrosis regression after antiviral therapy in patients with chronic hepatitis B].
Sun YM; Zhou JL; Wang L; Wu XN; Chen YP; Piao HX; Lu LG; Jiang W; Xu YQ; Feng B; Nan YM; Xie W; Chen GF; Zheng HW; Li H; Ding HG; Liu H; Lyu FD; Shao C; Wang TL; Ou XJ; Wang BQ; Chen SY; You H; Jia JD
Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):819-826. PubMed ID: 29325275
[No Abstract] [Full Text] [Related]
3. Regression of Liver Fibrosis in Patients on Hepatitis B Therapy Is Associated With Decreased Liver-Related Events.
Sun Y; Chen W; Chen S; Wu X; Zhang X; Zhang L; Zhao H; Xu M; Chen Y; Piao H; Li P; Li L; Jiang W; Li X; Xing H; Liu X; Zhang Y; Wang B; Zhou J; Meng T; Zhao X; Shao C; Kong Y; Zhao X; Ou X; Liu C; Jia J; You H
Clin Gastroenterol Hepatol; 2024 Mar; 22(3):591-601.e3. PubMed ID: 38040276
[TBL] [Abstract][Full Text] [Related]
4. Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy.
Huang R; Rao HY; Yang M; Gao YH; Wang J; Jin Q; Ma DL; Wei L
World J Gastroenterol; 2021 Feb; 27(5):404-415. PubMed ID: 33584072
[TBL] [Abstract][Full Text] [Related]
5. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir.
Kong Y; Sun Y; Zhou J; Wu X; Chen Y; Piao H; Lu L; Ding H; Nan Y; Jiang W; Xu Y; Xie W; Li H; Feng B; Shi G; Chen G; Li H; Zheng H; Cheng J; Wang T; Liu H; Lv F; Shao C; Mao Y; Sun J; Chen T; Han T; Han Y; Wang L; Ou X; Zhang H; Jia J; You H
J Viral Hepat; 2019 May; 26(5):576-585. PubMed ID: 30624000
[TBL] [Abstract][Full Text] [Related]
6. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment.
Sun Y; Zhou J; Wang L; Wu X; Chen Y; Piao H; Lu L; Jiang W; Xu Y; Feng B; Nan Y; Xie W; Chen G; Zheng H; Li H; Ding H; Liu H; Lv F; Shao C; Wang T; Ou X; Wang B; Chen S; Wee A; Theise ND; You H; Jia J
Hepatology; 2017 May; 65(5):1438-1450. PubMed ID: 28027574
[TBL] [Abstract][Full Text] [Related]
7. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.
Wang JL; Du XF; Chen SL; Yu YQ; Wang J; Hu XQ; Shao LY; Chen JZ; Weng XH; Zhang WH
World J Gastroenterol; 2015 Aug; 21(32):9598-606. PubMed ID: 26327767
[TBL] [Abstract][Full Text] [Related]
8. On-treatment changes of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon α add-on therapy.
Liu T; Sun Y; Zhou J; Yang F; Zou X; Wang L; Wu X; Chen Y; Piao H; Lu L; Jiang W; Xu Y; Feng B; Nan Y; Xie W; Chen G; Zheng H; Li H; Ding H; Liu H; Wang T; Ou X; Wu S; Kong Y; Wang P; Cong M; Zhang Y; You H; Jia J
J Med Virol; 2019 Aug; 91(8):1499-1509. PubMed ID: 30905065
[TBL] [Abstract][Full Text] [Related]
9. Predictive validation of qualitative fibrosis staging in patients with chronic hepatitis B on antiviral therapy.
Lee HW; Na K; Kim SU; Kim BK; Park JY; Nahm JH; Lee JI; Kim DY; Ahn SH; Han KH; Park YN
Sci Rep; 2019 Oct; 9(1):15628. PubMed ID: 31666552
[TBL] [Abstract][Full Text] [Related]
10. Liver fibrosis showed a two-phase regression rate during long-term anti-HBV therapy by three-time biopsies assessments.
Chen S; Zhou J; Wu X; Meng T; Wang B; Liu H; Wang T; Zhao X; Zhao X; Kong Y; Ou X; Jia J; Sun Y; You H
Hepatol Int; 2024 Jun; 18(3):904-916. PubMed ID: 38565833
[TBL] [Abstract][Full Text] [Related]
11. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.
Chang TT; Liaw YF; Wu SS; Schiff E; Han KH; Lai CL; Safadi R; Lee SS; Halota W; Goodman Z; Chi YC; Zhang H; Hindes R; Iloeje U; Beebe S; Kreter B
Hepatology; 2010 Sep; 52(3):886-93. PubMed ID: 20683932
[TBL] [Abstract][Full Text] [Related]
12. Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.
Hoefs JC; Shiffman ML; Goodman ZD; Kleiner DE; Dienstag JL; Stoddard AM;
Gastroenterology; 2011 Sep; 141(3):900-908.e1-2. PubMed ID: 21699796
[TBL] [Abstract][Full Text] [Related]
13. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.
Ji D; Chen Y; Bi J; Shang Q; Liu H; Wang JB; Tan L; Wang J; Chen Y; Li Q; Long Q; Song L; Jiang L; Xiao G; Yu Z; Chen L; Wang X; Chen D; Li Z; Dong Z; Yang Y
J Hepatol; 2022 Dec; 77(6):1515-1524. PubMed ID: 35985545
[TBL] [Abstract][Full Text] [Related]
14. Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B.
Kim HS; Kim BK; Kim SU; Park JY; Kim DY; Song KJ; Park JW; Kim YJ; Baatarkhuu O; Han KH; Ahn SH
Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1647-1656.e6. PubMed ID: 27305847
[TBL] [Abstract][Full Text] [Related]
15. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
[TBL] [Abstract][Full Text] [Related]
16. On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B.
Chang XJ; Sun C; Chen Y; Li XD; Yu ZJ; Dong Z; Bai WL; Wang XD; Li ZQ; Chen D; Du WJ; Liao H; Jiang QY; Sun LJ; Li YY; Zhang CH; Xu DP; Chen YP; Li Q; Yang YP
World J Gastroenterol; 2019 Aug; 25(32):4764-4778. PubMed ID: 31528100
[TBL] [Abstract][Full Text] [Related]
17. Effect of entecavir plus Ganshuang granule on fibrosis and cirrhosis in patients with chronic hepatitis B.
Lu F; Geng JB; Zhang JW; Dong Y
J Tradit Chin Med; 2021 Aug; 41(4):624-629. PubMed ID: 34392656
[TBL] [Abstract][Full Text] [Related]
18. Persistent steatosis correlates with decreased fibrosis regression during anti-HBV treatment in patients with chronic HBV infection.
Zhang M; Chen S; Wu X; Zhou J; Wang T; Liu H; Zhao X; Wang B; Zhao X; Kong Y; Soon GST; Ou X; Jia J; Chen W; Sun Y; You H
J Med Virol; 2023 Oct; 95(10):e29156. PubMed ID: 37822064
[TBL] [Abstract][Full Text] [Related]
19. Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy.
Seo YS; Kim MN; Kim SU; Kim SG; Um SH; Han KH; Kim YS
Medicine (Baltimore); 2016 Mar; 95(12):e2985. PubMed ID: 27015173
[TBL] [Abstract][Full Text] [Related]
20. Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B: A 78-week prospective study.
Dong XQ; Wu Z; Li J; Wang GQ; Zhao H;
J Gastroenterol Hepatol; 2019 Apr; 34(4):755-763. PubMed ID: 30290019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
